Drug Trial Radar · NCT04693169
[Al18F]PSMA137 PET/CT Imaging for PSMA-Positive Cancer Patients
Last checked: Nov 20, 2026Latest source record: Jan 25, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
20
Planned (sponsor's estimate)
Start
Jan 15, 2021
Primary completion
Jun 12, 2024
Study completion Dec 12, 2024
Sponsor
- Lead sponsor
- Peking University Cancer Hospital & InstituteAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Jan 5, 2021
Design
- Study type
- Interventional
- Phase
- Not applicable
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Diagnostic
- FDA-regulated drug
- No
- Who can join
- Male only, from 18 years, up to 90 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
To investigate the radioactive uptake of \[Al 18 F\]PSMA137 in PCa patients, and evaluate the ability of \[Al 18 F\]PSMA137 to detect PSMA overexpression in PCa patients (especially those with recurrent or advanced PCa).To provide an approach for screening patients high expression of PSMA, efficacy monitoring, drug resistance and early warning of recurrence and metastasis to achieve the individualized antitumor treatment of targeted drugs.
Conditions
- Prostate Cancer
Interventions
11C-CholineDrug
1、PSMA137 labeled with \[Al18F\] will be used as a molecular imaging tracer for PET/CT scanning。 2、11C-choline (0.05-0.1mCi/kg) was injected intravenously in a week after the \[Al18F\]PSMA137 PET/CT examination, and imaging of the head and body cadres was performed 20 min after the injection using Philips Gemini TF16 or Siemens Biograph M-CT flow PET/CT
Primary outcomes
What the sponsor says the trial is designed to measure.
- SUV(standardized uptake value)Time frame: 2 years
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Beijing Cancer Hospital
Beijing, Beijing Municipality, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.